Manel Esteller: The Epigenetic Hallmarks of Cancer
Manel Esteller, Director at Josep Carreras Leukaemia Research Institute, shared a post on X about his recent paper published in Cancer Discovery.
“Our Epigenetic Hallmarks of Cancer article in Cancer Discovery, American Association for Cancer Research. Epigenetic genes are among the most frequently mutated, such as DNMT3A, TET2, SMARCA4 (BRG1), and ARID1A (BA250).”
“The Epigenetic Hallmarks of Cancer”
Authors: Manel Esteller, Mark Dawson, Cigall Kadoch, Feyruz Rassool, Peter Jones, Stephen Baylin.
More posts featuring Manel Esteller.
Manel Esteller is the Group Leader of Cancer Epigenetics at the Josep Carreras Institute and serves as the Chairman of Genetics at the University of Barcelona’s School of Medicine. He is also an ICREA Research Professor.
His current research focuses on mapping the epigenome and epitranscriptome of both normal and transformed cells, examining the interactions between epigenetic modifications and non-coding RNAs, and developing new epigenetic drugs for cancer therapy.
Previously, Dr. Esteller directed the Cancer Epigenetics and Biology Program (PEBC) in Barcelona and led the Josep Carreras Leukaemia Research Institute (IJC).
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023